Literature DB >> 21255547

Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid.

J P Lee1, D K Kim, D Y Oh, J H Paik, K C Moon, S Kim, Y S Kim.   

Abstract

Thrombotic microangiopathy (TMA) is a rare renal complication accompanied with Castleman's disease. We report the first case of TMA combined plasma cell type multicentric Castleman's disease (MCD) which was successfully treated with rituximab and corticosteroid. A previously healthy 60-year-old Korean man was admitted due to acute renal failure, thrombocytopenia, and multiple lymphadenopathies. The result of lymph node biopsy was plasma cell type Castleman's disease and TMA was revealed by kidney biopsy. After treatment with rituximab, prednisolone and temporary hemodialysis, complete remission was achieved. The combination of corticosteroid and rituximab was associated with improvement for this patient.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255547     DOI: 10.5414/cn106491

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.

Authors:  Lucie M Turcotte; Colleen K Correll; Robyn C Reed; Christopher L Moertel
Journal:  Pediatr Blood Cancer       Date:  2013-09-09       Impact factor: 3.167

2.  A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: The first case report in Latin America.

Authors:  Fabio Freire José; Lucila Nassif Kerbauy; Guilherme Fleury Perini; Danielle Isadora Blumenschein; Denise da Cunha Pasqualin; Denise Maria Avancini Costa Malheiros; Guilherme de Carvalho Campos Neto; Fabio Pires de Souza Santos; Ronaldo Piovesan; Nelson Hamerschlak
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 3.  AA amyloidosis associated with Castleman disease: A case report and review of the literature.

Authors:  Luca Bernabei; Adam Waxman; Gabriel Caponetti; David C Fajgenbaum; Brendan M Weiss
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

Review 4.  TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.

Authors:  Kun-Hua Tu; Pei-Yi Fan; Tai-Di Chen; Wen-Yu Chuang; Chao-Yi Wu; Cheng-Lung Ku; Ya-Chung Tian; Chih-Wei Yang; Ji-Tseng Fang; Huang-Yu Yang
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.